Mass changes in remnant cholesterol and LDL cholesterol explain part of the results of gemfibrozil and non-gemfibrozil fibrate trials

Publikation: Bidrag til tidsskriftKommentar/debatForskningfagfællebedømt

TidsskriftJournal of Internal Medicine
Udgave nummer5
Sider (fra-til)707-710
StatusUdgivet - 2024

Bibliografisk note

Funding Information:
Capital Region of Denmark [research fund to TD], Grant Number: A7165 and A7272; Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Denmark, Japan Society for the Promotion of Science, JSPS: Postdoctoral Fellowship for Research Abroad to TD, Grant Number: 202360405. The funders had no direct role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

ID: 383885109